Meridian Bioscience (VIVO) Releases Earnings Results, Reports EPS of $0.24 EPS

Meridian Bioscience (VIVO) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $0.24 EPS for the quarter. Analysts had a consensus estimate of $0.24. The company posted revenue of $51.30 million in the period, compared to analysts expectations of $52.08 million. The company’s revenue was down -.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS.

Many Wall Street Analysts have commented on Meridian Bioscience. Company shares were Reiterated by Canaccord Genuity on Mar 28, 2016 to “Hold”, Firm has raised the Price Target to $ 19 from a previous price target of $18 .

Meridian Bioscience opened for trading at $20.6 and hit $20.74 on the upside on Wednesday, eventually ending the session at $20.69, with a gain of 0.68% or 0.14 points. The heightened volatility saw the trading volume jump to 1,84,978 shares. Company has a market cap of $870 M.

In a different news, on Dec 10, 2015, Vecheslav A Elagin (EVP, Research & Development) sold 7,500 shares at $19.75 per share price. According to the SEC, on Dec 2, 2015, Richard Eberly (EVP,Pres Meridian Life Science) sold 4,934 shares at $19.61 per share price. On Nov 24, 2015, John Mcilwraith (director) purchased 1,000 shares at $20.19 per share price, according to the Form-4 filing with the securities and exchange commission.

Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Meridian Bioscience

Leave a Reply

Meridian Bioscience - Is it time to Sell?

Top Brokerage Firms are advising their investors on Meridian Bioscience. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.